New treatment for fatty liver disease

Hadasit, the Hadassah Medical Organization’s technology transfer company, and Israel’s BioLineRx are to develop a treatment BL-1210 for non-alcoholic steatohepatitis (NASH) or fatty liver disease.  It modulates the immune system to reduce scarring that leads to cirrhosis.  There is currently no FDA approved treatments.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *